Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs. The group in-licenses, develops promising drug candidates. It develops its products for global registration and access to the largest number of patients worldwide. The products are out-licensed to pharmaceutical partners for sales and marketing.
Besides drug development, Debiopharm has recently developed in-house skills in the field of companion diagnostics with a view to benefit from the key opportunities in personalized medicine.
Debiopharm Group independently funds the worldwide development of all of its products while providing expertise in all areas.
Site web: https://www.debiopharm.com